Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function.

• The safety and effects of a fixed low dose of growth hormone (GH), 0.17 mg/day was evaluated for 3 months, on glucose metabolism, serum lipids, body composition and cardiac function in 53 GH deficient adults aged 18-78 years. Body composition was determined by dual energy X-ray absorptiometry and total body water was determined by bioelectrical impedance. Echocardiography was used to assess cardiac function and bicycle ergonometry was used to determine exercise capacity. All investigations were performed at baseline and after 3 months. At 3 months, serum levels of insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3 and lipoprotein (a) and lean body mass were increased (P<0.05). Total and low density lipoprotein cholesterol levels and fat mass were reduced (P<0.05). There was an increase in the serum glucose value at 120 min after an oral glucose tolerance test performed at 3 months (P<0.05), no other changes in glucose metabolism or in cardiac function were noted. Side-effects were few and mild. This fixed low-dose regime resulted in improvements in body composition and lipid profile, without causing serious side effects. This is therefore a valid method to institute GH replacement in adults.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Nyckelord

Adult

Blood Glucose

drug effects

metabolism

Body Composition

drug effects

Body Mass Index

Cardiovascular System

drug effects

Dose-Response Relationship

Drug

Electrocardiography

drug effects

Exercise Test

Female

Homeostasis

Hormone Replacement Therapy

Human Growth Hormone

deficiency

therapeutic use

Humans

Insulin-Like Growth Factor Binding Protein 3

blood

Insulin-Like Growth Factor I

metabolism

Lipoproteins

blood

drug effects

Male

Middle Aged

Pituitary Diseases

drug therapy

etiology

Recombinant Proteins

therapeutic use

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)